vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $333.4M, roughly 1.0× PRA GROUP INC). PRA GROUP INC runs the higher net margin — 17.0% vs 13.2%, a 3.8% gap on every dollar of revenue. On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-90.4M). Over the past eight quarters, PRA GROUP INC's revenue compounded faster (14.2% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
HAE vs PRAA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $333.4M |
| Net Profit | $44.7M | $56.5M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 37.7% |
| Net Margin | 13.2% | 17.0% |
| Revenue YoY | -2.7% | 13.7% |
| Net Profit YoY | 19.3% | 206.3% |
| EPS (diluted) | $0.95 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $333.4M | ||
| Q3 25 | $327.3M | $311.1M | ||
| Q2 25 | $321.4M | $287.7M | ||
| Q1 25 | $330.6M | $269.6M | ||
| Q4 24 | $348.5M | $293.2M | ||
| Q3 24 | $345.5M | $281.5M | ||
| Q2 24 | $336.2M | $284.2M | ||
| Q1 24 | — | $255.6M |
| Q4 25 | $44.7M | $56.5M | ||
| Q3 25 | $38.7M | $-407.7M | ||
| Q2 25 | $34.0M | $42.4M | ||
| Q1 25 | $58.0M | $3.7M | ||
| Q4 24 | $37.5M | $18.5M | ||
| Q3 24 | $33.8M | $27.2M | ||
| Q2 24 | $38.4M | $21.5M | ||
| Q1 24 | — | $3.5M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 37.7% | ||
| Q3 25 | 17.9% | -101.4% | ||
| Q2 25 | 16.8% | 29.6% | ||
| Q1 25 | 21.6% | 27.7% | ||
| Q4 24 | 16.9% | 32.1% | ||
| Q3 24 | 15.0% | 32.0% | ||
| Q2 24 | 11.8% | 31.4% | ||
| Q1 24 | — | 26.0% |
| Q4 25 | 13.2% | 17.0% | ||
| Q3 25 | 11.8% | -131.0% | ||
| Q2 25 | 10.6% | 14.7% | ||
| Q1 25 | 17.5% | 1.4% | ||
| Q4 24 | 10.8% | 6.3% | ||
| Q3 24 | 9.8% | 9.6% | ||
| Q2 24 | 11.4% | 7.6% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | $0.95 | $1.47 | ||
| Q3 25 | $0.81 | $-10.43 | ||
| Q2 25 | $0.70 | $1.08 | ||
| Q1 25 | $1.17 | $0.09 | ||
| Q4 24 | $0.74 | $0.47 | ||
| Q3 24 | $0.66 | $0.69 | ||
| Q2 24 | $0.74 | $0.54 | ||
| Q1 24 | — | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $104.4M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $979.9M |
| Total Assets | $2.5B | $5.1B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $104.4M | ||
| Q3 25 | $296.4M | $107.5M | ||
| Q2 25 | $292.9M | $131.6M | ||
| Q1 25 | $306.8M | $128.7M | ||
| Q4 24 | $320.8M | $105.9M | ||
| Q3 24 | $299.3M | $141.1M | ||
| Q2 24 | $344.4M | $118.9M | ||
| Q1 24 | — | $108.1M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $979.9M | ||
| Q3 25 | $849.2M | $928.5M | ||
| Q2 25 | $882.3M | $1.3B | ||
| Q1 25 | $820.8M | $1.2B | ||
| Q4 24 | $906.9M | $1.1B | ||
| Q3 24 | $878.9M | $1.2B | ||
| Q2 24 | $905.4M | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $2.5B | $5.1B | ||
| Q3 25 | $2.4B | $5.0B | ||
| Q2 25 | $2.5B | $5.4B | ||
| Q1 25 | $2.5B | $5.1B | ||
| Q4 24 | $2.5B | $4.9B | ||
| Q3 24 | $2.5B | $4.9B | ||
| Q2 24 | $2.5B | $4.7B | ||
| Q1 24 | — | $4.5B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $-85.5M |
| Free Cash FlowOCF − Capex | $87.2M | $-90.4M |
| FCF MarginFCF / Revenue | 25.7% | -27.1% |
| Capex IntensityCapex / Revenue | 1.9% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.09× | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $-85.5M | ||
| Q3 25 | $111.3M | $-10.1M | ||
| Q2 25 | $17.4M | $-12.9M | ||
| Q1 25 | $116.6M | $-52.6M | ||
| Q4 24 | $43.8M | $-94.6M | ||
| Q3 24 | $48.8M | $-35.0M | ||
| Q2 24 | $-27.4M | $-29.5M | ||
| Q1 24 | — | $-73.0M |
| Q4 25 | $87.2M | $-90.4M | ||
| Q3 25 | $106.3M | $-11.3M | ||
| Q2 25 | $13.6M | $-14.2M | ||
| Q1 25 | $100.9M | $-53.5M | ||
| Q4 24 | $35.2M | $-98.6M | ||
| Q3 24 | $39.4M | $-36.1M | ||
| Q2 24 | $-33.1M | $-30.8M | ||
| Q1 24 | — | $-73.5M |
| Q4 25 | 25.7% | -27.1% | ||
| Q3 25 | 32.5% | -3.6% | ||
| Q2 25 | 4.2% | -4.9% | ||
| Q1 25 | 30.5% | -19.8% | ||
| Q4 24 | 10.1% | -33.6% | ||
| Q3 24 | 11.4% | -12.8% | ||
| Q2 24 | -9.8% | -10.8% | ||
| Q1 24 | — | -28.8% |
| Q4 25 | 1.9% | 1.4% | ||
| Q3 25 | 1.5% | 0.4% | ||
| Q2 25 | 1.2% | 0.4% | ||
| Q1 25 | 4.7% | 0.3% | ||
| Q4 24 | 2.5% | 1.4% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 1.7% | 0.5% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | 2.09× | -1.51× | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | -0.30× | ||
| Q1 25 | 2.01× | -14.37× | ||
| Q4 24 | 1.17× | -5.13× | ||
| Q3 24 | 1.44× | -1.29× | ||
| Q2 24 | -0.71× | -1.37× | ||
| Q1 24 | — | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
